Back Hepatitis B Hepatitis B Topics HBV Treatment

Updated Entecavir Label Expands Indication for Children with Hepatitis B

The U.S. Food and Drug Administration (FDA) last week approved new label information for entecavir (Baraclude), a nucleoside analog used to treat chronic hepatitis B virus (HBV) infection. The revised label expands the indication for pediatric use by children age 2 years and up.

alt

Read more:

Chronic Hepatitis B Treatment Guidelines

CHB Treatment Guideline Navigator

Mark Sulkowski from Johns Hopkins and Tram Tran from Cedars Sinai Medical Center help readers understand and make decisions using current guidelines for treatment of people with chronic hepatitis B. This continuing medical education (CME) activity is available for free to all, with credit available for physicians and nurses.

alt

Read more:

Adding Pegylated Interferon to Antivirals for Hepatitis B May Lead to HBsAg Loss

Addition of pegylated interferon to nucleoside/nucleotide antivirals increases the likelihood of hepatitis B surface antigen (HBsAg) loss -- considered a cure -- in people with hepatitis B "e" antigen (HBeAg) negative chronic hepatitis B, according to a report in December 2013 edition of Journal of Clinical Virology.

alt

Read more:

Monitoring Inactive Hepatitis B Is Cost-effective but Must Increase to Improve Survival

Lifelong monitoring of people with inactive hepatitis B virus (HBV) infection may be cost-effective, according to a study in China published the December 19 advance online edition of Hepatology. Monitoring and treatment would have to be substantially expanded, however, to achieve significant reductions in liver cancer and hepatitis B-related mortality.

alt

Read more:

AASLD 2013: Tenofovir for Hepatitis B Remains Safe and Effective Over 7 Years

Chronic hepatitis B patients treated with tenofovir (Viread) for 7 years continued to main viral suppression and liver enzyme normalization, while serological response rates continued to increase, according to a poster presented at the 64th AASLD Liver Meeting last month in Washington, DC. Long-term kidney and bone-related side effects remained uncommon.

alt

Read more: